CDSCO targets 18-month rollout for end-to-end digital drug regulation platform
India’s drug regulator plans a platform spanning manufacturing, approvals, distribution and post-market surveillance. CDSCO is also piloting AI tools, QR-authenticated GMP/COPP certificates and faster pathways for innovative therapies.
What happened
Central Drugs Standard Control Organisation (CDSCO) · CDSCO will launch a digital platform covering India’s drug regulatory chain, including manufacturing,
Key facts
- 18 months
- more than 99%
- 25–30%
- more than 800 startups
- 24 countries
- 1.4 billion
Why this matters
Pharma, retail-health and supply-chain buyers should prioritise targets with regulatory-tech, serialization, AI compliance and post-market surveillance capabilities ahead of CDSCO’s planned rollout.
What to watch
- Publication of CDSCO platform architecture, mandatory data fields, interoperability standards and phased compliance dates.
- Whether QR-authenticated GMP/COPP certificates become mandatory for procurement, import, tendering or product release.
- Pilot results for AI-enabled review, including measurable reductions in approval timelines and any human-review safeguards.
- Rules requiring batch-level traceability across wholesalers, pharmacies, e-pharmacies and marketplaces.
- Enforcement actions, recalls or licence suspensions linked to incomplete digital records or counterfeit-risk findings.
- Adoption by large hospital chains, government procurement agencies, e-pharmacies and organised retail pharmacy groups.
- Evidence of supplier consolidation, generic-drug stock-outs or procurement-price increases during onboarding.
- Map exposure to suppliers that lack robust GMP, batch-level traceability, digital documentation or CDSCO-ready regulatory workflows.
- Prioritise integration of purchase-order, batch, expiry, recall and supplier-licence data with pharmacy ERP and warehouse-management systems.
- Build a preferred-supplier scorecard combining GMP status, certificate authenticity, recall history, cold-chain performance and digital data readiness.
- Prepare customer-facing authentication features, including QR/batch verification for high-risk, high-value and chronic-care medicines.
- Expand pharmacist and customer-service protocols for recalls, adverse-event escalation, prescription validation and innovative-therapy counselling.
- Assess opportunities to add specialty-pharmacy, diagnostics, cold-chain and patient-adherence services as faster approvals broaden product availability.